Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 8/20 | 0.51 |
| ▸ | REN | P00797 | 3/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21724644 | 1.00 | CTSL (0.55) | CTSLCTSBCTSSCTSKBACE1 | |
| SCHEMBL3493240 | 0.93 | BACE1 (0.52) | CTSLCTSBCTSSCTSKBACE1 | |
| SCHEMBL27350811 | 0.89 | CTSL (0.68) | CTSLCTSBCTSSCTSKREN | |
| SCHEMBL4576781 | 0.89 | CTSL (0.68) | CTSLCTSBCTSSCTSKREN | |
| SCHEMBL7392267 | 0.89 | CTSL (0.68) | CTSLCTSBCTSSCTSKREN | |
| SCHEMBL25977614 | 0.89 | CTSL (0.68) | CTSLCTSBCTSSCTSKREN | |
| SCHEMBL30910744 | 0.88 | CTSL (0.51) | CTSLCTSBCTSSCTSKBACE1 | |
| SCHEMBL5072619 | 0.86 | CTSS (0.44) | CTSLCTSBCTSSCTSKBACE1 | |
| SCHEMBL30096350 | 0.86 | ECE1 (0.46) | CTSLCTSBCTSSCTSKBACE1 | |
| Aminomethylamide SCHEMBL9737800 | 0.86 | CTSL (0.57) | CTSLCTSBCTSSCTSKREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11998610-B2 | Conjugates and methods of using the same | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-3836971-A1 | CONJUGATES AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020037009-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998610-B2 | Conjugates and methods of using the same | CD47, CD44, CD74 | CTSL 390/4885CTSB 823/4885CTSS 653/4885 |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | CTSL 390/4885CTSB 823/4885CTSS 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.